Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eton Pharmaceutcials Inc (ETON)

Eton Pharmaceutcials Inc (ETON)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 104,091
  • Shares Outstanding, K 17,763
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,740 K
  • 60-Month Beta N/A
  • Price/Sales 208.18
  • Price/Cash Flow N/A
  • Price/Book 6.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.28
  • Number of Estimates 2
  • High Estimate -0.22
  • Low Estimate -0.33
  • Prior Year -2.24
  • Growth Rate Est. (year over year) +87.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.44 +3.13%
on 11/11/19
6.92 -18.93%
on 10/22/19
-0.45 (-7.43%)
since 10/18/19
3-Month
5.13 +9.36%
on 09/05/19
7.49 -25.09%
on 09/20/19
-0.05 (-0.88%)
since 08/16/19
52-Week
5.13 +9.36%
on 09/05/19
10.20 -45.00%
on 05/13/19
-0.49 (-8.03%)
since 11/16/18

Most Recent Stories

More News
Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has entered into a $10 million debt facility...

ETON : 5.61 (-4.27%)
Eton Pharmaceuticals to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report third quarter 2019 financial...

ETON : 5.61 (-4.27%)
Eton Pharmaceuticals, Inc. (ETON) Upgraded to Strong Buy: Here's What You Should Know

Eton Pharmaceuticals, Inc. (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ETON : 5.61 (-4.27%)
Eton Pharmaceuticals to Participate in Lake Street 3rd Annual Best Ideas Growth Conference

Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer,...

ETON : 5.61 (-4.27%)
Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4

Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.

NBRV : 1.84 (-3.16%)
FGEN : 36.87 (-0.32%)
ETON : 5.61 (-4.27%)
CELC : 11.17 (-14.27%)
Eton Pharmaceuticals Announces Positive Results from Clinical Study Report of ET-104

--New Drug Application (NDA) Submission Expected in Fourth Quarter of 2019

ETON : 5.61 (-4.27%)
Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD

Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).

ACOR : 1.62 (-10.25%)
CLDX : 2.13 (-5.95%)
ETON : 5.61 (-4.27%)
KDMN : 4.13 (+5.36%)
Regeneron Ebola Treatment Shows Promise, Study Stopped Early

Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.

REGN : 340.19 (-1.36%)
CLDX : 2.13 (-5.95%)
ACOR : 1.62 (-10.25%)
ETON : 5.61 (-4.27%)
Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates

Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.

BGNE : 196.01 (-1.13%)
EPZM : 15.42 (+0.39%)
ACOR : 1.62 (-10.25%)
ETON : 5.61 (-4.27%)
Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View

Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.

GALT : 3.09 (-4.33%)
PTLA : 28.05 (+3.09%)
BHC : 28.40 (-0.28%)
ETON : 5.61 (-4.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ETON with:

Business Summary

Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.

See More

Key Turning Points

2nd Resistance Point 6.03
1st Resistance Point 5.82
Last Price 5.61
1st Support Level 5.45
2nd Support Level 5.29

See More

52-Week High 10.20
Fibonacci 61.8% 8.26
Fibonacci 50% 7.66
Fibonacci 38.2% 7.07
Last Price 5.61
52-Week Low 5.13

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar